A meta-analysis of 19 studies found that pediatric patients with hidradenitis suppurativa (HS) show an increased rate of ...

The assessment of Crohn's disease activity through endoscopy is a cornerstone of both clinical management and research. In The Lancet Gastroenterology & Hepatology, Christopher Ma and colleagues ...

SEOUL, June 9 (Yonhap) -- South Korean chip giant SK hynix Inc. ranked first in operating profit among 1,000 major listed ...

Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. Leveraging ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

South Korea has promised fresh measures for its major export industries, from biopharmaceutical makers to car producers, as the country braces for the economic impact of U.S. tariffs imposed by Trump.

INCHEON, South Korea, May 21, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for YUFLYMA ...

Celltrion announced on the 20th that it has decided to repurchase its own shares worth approximately 100 billion won through its board of directors. The shares to be repurchased this time total ...

Abpro Holdings, Inc. and Celltrion have announced a strategic partnership for the global development of ABP-102/CT-P72, a bispecific T-cell engager designed to target HER2-positive cancers ...

ABP-102/CT-P72, a tetravalent bispecific HER2 x CD3 T-cell engager co-developed with Celltrion, is engineered to selectively target HER2-overexpressing tumors while reducing the risk of on-target ...

The US Food and Drug Administration (FDA) has designated Celltrion’s Yuflyma (adalimumab-aaty) as an interchangeable biosimilar to AbbVie’s Humira (adalimumab). The decision allows Yuflyma to be ...

Remdantry™ (previously known as Inflectra®), developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar infliximab in Canada and will be commercially available across ...